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Ovarian cancer is the most lethal gynaecological malignancy in North America and remains
one  of the most difﬁcult cancers to manage. Although the 5-year survival rates are high when
the  disease is diagnosed early, this decreases exponentially in late-stage diagnoses and due
to the current lack of screening methods, ovarian cancer is often diagnosed in its later stages
when  the cancer has progressed considerably. To exacerbate this, ovarian cancer patients
almost  always experience recurrence and resistance to chemotherapy after an initial pos-
itive  response to treatment. Clearly, new modalities of clinical management are neededOvarian cancer
Personalized medicine
Mass  spectrometry
Proteomics
Chemoresistance
for  this deadly disease. With the recent advent of high-throughput proteomic technologies,
there  have been numerous efforts to proﬁle ovarian cancer using mass spectrometry to
identify  novel biomarkers for various clinical applications including diagnosis, prognosis,
therapeutic  targets, and monitoring therapeutic response. Identifying such novel biomark-
ers  would allow for better tailoring of disease prevention and treatment on an individualbasis  in order to improve patient outcome. Unfortunately, traditional bottom-up proteomics
Abbreviations: OvCa, ovarian cancer; BRCA 1/2, breast cancer susceptibility gene 1/2; MS, mass spectrometry; PI3K, phosphoinositide
3-kinase;  CA125, carbohydrate antigen 125; HE4, human epididymal protein4; FDA, food and drug administration; WFDC2, whey acidic
protein four-disulﬁde core domain protein 2; EOC, epithelial ovarian carcinoma; ROMA, Risk of Ovarian Malignancy Algorithm; LMP, low
malignant potential; RMI, Risk of Malignancy Index; m/z, mass-to-charge; PTM, post-translational modiﬁcation; MALDI, matrix-assisted
laser desorption/ionization; ESI, electrospray ionization; BOT, benign ovarian tumour; UPLC, ultra performance liquid chromatogra-
phy; Q-TOF, quadrupole time-of-ﬂight; LC, liquid chromatography; CPG, 27-nor-5-cholestane-3,7,12,24,25 pentol glucuronide; AUC, area
under the curve; ROC, receiver operator characteristic; PRoBE, prospective-specimen-collection, retrospective-blinded evaluation; VEGF-
A, vascular endothelial growth factor A; PFS, progression-free survival; PARP, poly(ADP-ribose) polymerase; 2-DE, 2-dimensional gel
electrophoresis;
 
ICAT,
 
isotope-coded
 
afﬁnity
 
tag;
 
iTRAQ,
 
isobaric
 
tag
 
for
 
relative
 
and
 
absolute
 
quantiﬁcation.
                 
∗ Corresponding author at: 200 Elizabeth Street, Room 3 EB 362A, Toronto, Ontario M5G 2C4, Canada. Tel.: +1 416 340 4800x8589;
fax:  +1 416 340 4215.
E-mail  addresses: felix.leung@mail.utoronto.ca (F. Leung), natasha.musrap@mail.utoronto.ca (N. Musrap), ediamandis@mtsinai.on.ca
(E.P. Diamandis), vathany.kulasingam@uhn.ca (V. Kulasingam).
1 1These authors contributed equally.
2212-9634 ©  2013 The Authors. Published by Elsevier B.V. 
http://dx.doi.org/10.1016/j.trprot.2013.08.001
Open access under CC BY-NC-SA license. 
t r a n s l a t i o n a l p r o t e o m i c s 1 ( 2 0 1 3 ) 74–86 75
have not yielded any markers able to pass stringent clinical validation. As a result, many
alternative  strategies have recently emerged where mass spectrometry is employed in a
complementary fashion to traditional shotgun proteomics. In this review, we  will examine
such  complementary mass spectrometry-based biomarker discovery efforts with a focus on
early diagnostic markers and markers of chemoresistance.
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.  Introduction
varian cancer (OvCa) is the most lethal of all gynaecologi-
al malignancies and is the 5th leading cause of mortality due
o  cancer in North American women [1]. Despite advances in
edicine and technology, the survival rate of women  diag-
osed  with OvCa has remained relatively unchanged over the
ast  three decades [2–4]. Women  diagnosed with early-stage
vCa  have a 5-year survival rate of approximately 80–90% but
his  decreases dramatically to 20–30% in late-stage diagnoses
5].  Unfortunately, no reliable mode of screening currently
xists  for early detection of OvCa and the disease is often
symptomatic during its early stages. As a consequence, most
omen  are diagnosed when the disease has progressed con-
iderably.
In  addition to early detection, the treatment and manage-
ent  of OvCa patients faces several challenges. In general,
atients diagnosed with advanced disease are managed with
urgical  cytoreduction and chemotherapy. Although these
herapeutic  interventions are initially efﬁcacious, patients
ften  experience cancer recurrence, as a result of intrinsic
r  acquired chemoresistance by cancer stem cells or aber-
ant  expression of oncogenes and tumour suppressor genes
n  tumour cells. OvCa is not a single disease but rather a
instance,  high-grade serous carcinomas arise from the ovary
or  fallopian tube and display a high frequency of p53 and
BRCA1/2  mutations [6], whereas clear cell and endometrioid
tumours have been linked to endometriosis and harbour
PI3K  mutations [7]. Moreover, mucinous ovarian carcinomas,
which  comprise the least common subtype, are considered
to  be secondary metastases to the ovary from other tumours,
particularly those found in the gastrointestinal tract [8]. Due
to  the widespread heterogeneity among ovarian cancers,
standard conventional therapies often elicit varying treat-
ment  responses within the various subclasses of tumours. For
example, clear cell carcinomas often exhibit lower response
rates  in comparison to high-grade serous tumours following
administration of platinum-based drugs [9]. For these reasons,
the  ability to make deﬁnitive subtype diagnoses in order to
treat  patients accordingly would be extremely useful. The
notion  of treating patients on such an individual basis, also
known  as personalized medicine, has thus become a much
desired  model of care for OvCa patients.
Personalized medicine is deﬁned as the utilization of an
individual’s biological proﬁle to guide decisions in the pre-
vention  and clinical management of diseases. Within OvCa,
it  has become increasingly apparent that each subtype rep-
resents  a distinct genetic and etiological disease that simply
shares  a common anatomical location. Thus, it is imperative
Open access under CC BY-NC-SA license.eterogeneous group of tumours that can be classiﬁed into
istinct  molecular and histological subtypes, as they can
erive  from various ovarian and non-ovarian tissues and
ach  display their own germline and somatic mutations. Forto  delineate the differences between each subtype as well
as  understand the molecular processes by which tumours
acquire resistance in order to construct therapeutic inter-
ventions  that could be tailored on an individual basis. Such
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approaches to personalized medicine has been the focus of
the majority of OvCa studies as comprehensive characteri-
zation of the subtypes would greatly aid in the development
of subtype-speciﬁc management, which in turn would greatly
improve patient outcome.
With the recent advent of high-throughput technologies,
numerous studies have been undertaken to proﬁle the sub-
types of OvCa using genomic, transcriptomic and proteomic
approaches in order to identify subpopulations that could
potentially beneﬁt from personalized medicine. Speciﬁcally,
proteomic proﬁling of OvCa has mainly revolved around the
analysis of OvCa cell lines, tissues, and proximal ﬂuids using
mass spectrometry (MS). This has led to the identiﬁcation
of numerous altered protein expression patterns of the dis-
ease. The study of protein expression in OvCa has been
increasingly important as proteins are the mediators of all
biological processes and the molecular targets of the major-
ity of drugs. Moreover, the proteome integrates the cellular
genetic information and environmental inﬂuences. As such,
MS has been increasingly implemented as this platform allows
for the simultaneous examination of thousands of proteins
in biospecimens relevant to OvCa, and has more  recently
been applied to identiﬁcation of post-translational modiﬁca-
tions and metabolomic changes that occur during the disease.
Such technologies yield information that may be useful for
the diagnosis and treatment of patients through the discov-
ery of markers for prognosis, prediction, disease monitoring,
and response to chemotherapy. Despite these advantages and
promises, the era of proteomics has yet to deliver the expected
goods (novel biomarkers that will have an impact on clinical
management). As such, a number of alternative approaches to
biomarker discovery have emerged utilizing the power of MS.
In this review, an overview of several different MS-based
initiatives to uncover markers and signatures of OvCa will
be discussed such as glycomics and metabolomics (Fig. 1). In
the latter half of the review, various comparative proteomic
studies that uncover mechanisms of chemoresistance – in
particular, the efforts to ﬁnd novel therapeutic targets or mark-
ers for the purposes of monitoring or predicting treatment
response will be examined (Fig. 1).
2.  Current  status  of  OvCa  diagnosis
Current modalities for detecting OvCa are primarily based
on imaging and serological biomarkers. Women who are
suspected to have a mass (of unknown origin) through
physical pelvic examination will be subjected to transvagi-
nal ultrasonography and a blood test for carbohydrate
antigen-125 (CA125). Once the presence of a mass has
been conﬁrmed, its malignant potential must be determined
through exploratory laparotomy and subsequent biopsies.
Unfortunately, these techniques suffer from low speci-
ﬁcity, are invasive and carry their own inherent risks; as
such, there has been an increased focus on developing
serum-based detection methods due to their efﬁciency and
non-invasiveness.
Since its discovery in 1981 by Bast et al. [10], CA125 – also
known as mucin 16 – still remains the best serum biomarker
for the management of OvCa. It was identiﬁed through the i c s 1 ( 2 0 1 3 ) 74–86
development of a monoclonal antibody (OC125) that dis-
played reactivity with epithelial ovarian carcinoma (EOC) cell
lines and tissues from OvCa patients. Currently, CA125 is
approved as a serum marker for both monitoring treatment
with chemotherapy and differential diagnosis of patients pre-
senting with a pelvic mass, though the evidence for the latter
use stems only from large prospective studies. Unfortunately,
a major caveat of CA125 is that it is produced by coelomic
epithelium which is the progenitor for mesothelial, Müllerian,
pleural, pericardial and peritoneal tissues [11]. As a result,
CA125 displays poor speciﬁcity for OvCa as increased CA125
levels can be a result of other pathological states such as heart
failure, peritoneal infection, pericarditis, and benign gynae-
cological conditions [12–14]. For these reasons, CA125 is not
approved for OvCa screening or for the detection of early dis-
ease.
Human epididymal protein 4 (HE4) is another serum OvCa
biomarker that is becoming increasingly used in the clinic
since its approval by the FDA in 2009. Also known by its
gene name WFDC2 (whey acidic protein four-disulﬁde core
domain protein 2), HE4 was initially identiﬁed as an mRNA
transcript speciﬁc to the distal epididymal tissue [15]. Through
microarray gene-expression proﬁling, it was discovered that
HE4 was moderately expressed in lung adenocarcinomas,
breast carcinomas, transitional cell endometrial carcinomas
and pancreatic carcinomas, but consistently highly expressed
in ovarian carcinomas [16–19]. Furthermore, Drapkin et al.
showed that HE4 is relatively speciﬁc to the serous subtype
of epithelial ovarian carcinomas (EOCs), as expression was
observed in approximately 93% of serous carcinomas but it
was also present in a smaller proportion of endometrioid,
mucinous, and clear cell carcinomas [20]. Taken together,
there was strong evidence that this secreted glycoprotein
was a putative serum marker for ovarian cancer. In a pilot
study measuring serum levels of HE4 in ovarian cancer
patients, Hellstrom et al. concluded that HE4 may be com-
parable to CA125 as a monitoring serum tumour marker as
both displayed a sensitivity of 80% and a speciﬁcity of 95%
when used to classify blinded late stage cases and healthy
controls [21]. HE4 was approved by the FDA in 2009 as a
serum marker for monitoring recurrence of ovarian can-
cer.
A ﬁnal approach to OvCa diagnosis that is becoming
increasingly prevalent is the use of multimarker panels
derived from high-throughput discovery efforts. The ratio-
nale is that the use of multiple markers may provide a more
accurate representation of whether or not disease is present
especially when the disease (such as OvCa) is heterogeneous
across different individuals. In a study by Yurkovetsky et al.,
it was determined that from a list of 96 potential OvCa serum
biomarkers, a panel of CA125, HE4, carcinoembryonic antigen,
and vascular cell adhesion molecule 1 displayed a sensitivity
of 86% for early-stage OvCa and 93% for late-stage OvCa at a set
speciﬁcity of 98% when used to diagnose OvCa patients from
healthy controls [22]. The authors were able to further validate
this model on an independent blinded validation cohort while
additionally showing that the panel was speciﬁc to OvCa as
it displayed sensitivities of 33% for benign pelvic disease, 6%
for breast cancer, 0% for colorectal cancer, and 36% for lung
cancer.
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Fig. 1 – Diagrammatic representation of the various MS-based strategies used in the quest to identify biomarkers for
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can be subsequently identiﬁed through the mass spectrumvarian cancer, diagnosis and chemotherapy treatment resp
Furthermore, two other multimarker-based algorithms
ave recently gained FDA-approval for the discrimination of
enign versus malignant pelvic masses – the Risk of Ovar-
an Malignancy Algorithm (ROMA) and the OVA1TM test. The
OMA incorporates serum levels of CA125 and HE4, which
as identiﬁed through microarray studies, while the OVA1TM
est incorporates serum levels of CA125 and four other mark-
rs identiﬁed through MS  (beta-2 microglobulin, transferrin,
ransthyretin, apolipoprotein A1). The ROMA has been inves-
igated in multiple studies that have conﬁrmed its clinical
tility. In one such study, Moore et al. combined serum HE4
nd CA125 with menopausal status to create the predictive
ogistic regression model/algorithm known as ROMA. A total
f 531 patients consisting of 352 benign tumours, 129 EOCs,
2 low malignant potential (LMP) tumours, 6 non-EOCs and 22
on-ovarian cancers were evaluated. It was determined that
OMA could distinguish benign tumours from EOCs and LMP
umours with 89% sensitivity and 75% speciﬁcity. Though the
lgorithm performed much better in the postmenopausal pop-
lation, the authors were able to conﬁrm the clinical utility of
OMA to aid in stratifying patients with a pelvic mass into
isk groups. In a subsequent study, the authors had conﬁrmed
he superiority of ROMA over the existing Risk of Malignancy
ndex (RMI) in identifying women who will develop EOC when
hey initially present with a pelvic mass of unknown malig-
ant potential [23]. In this study, the ROMA had achieved a
ensitivity of 94% compared to 85% for the RMI at a set speci-
city of 75% for discriminating benign pelvic masses from
OCs in a cohort of 457 pelvic mass patients. While the OVA1TM
est showed promise during the clinical trial leading up to its
pproval by the FDA as a supplementary for clinical decision-
aking for preoperative adnexal mass patients, subsequent
tudies have reported conﬂicting results. Moore et al. [24]
eported that the addition of the seven biomarkers identiﬁed
y the inventors of the OVA1TM test to CA125 did not improve
he sensitivity for preclinical diagnosis compared to CA125
lone, but other studies have reported the beneﬁts of adding
ifferent combinations of the seven biomarkers to CA125 for
istinguishing benign from malignant pelvic masses [25,26].
espite the initial excitement over such multimarker pan-
ls, more  multi-institutional studies are required before the.
true clinical applicability of these new tests/algorithms can
be determined.
Consequently, there is now a renewed interest for the dis-
covery of novel serum biomarkers, especially for those that
can complement CA125. A serum-based test is ideal since
it would be minimally invasive, requiring a small drawing
of blood. Unfortunately, the majority of serum biomarker
candidates identiﬁed through high-throughput proteomic
experiments have been irreproducible and unable to pass
independent, blinded validation experiments. This may be
because upregulated proteins in the serum of OvCa patients
are often acute phase reactants that are a reﬂection of
the epiphenomena not speciﬁc to OvCa. Furthermore, many
serum biomarker discovery studies have focused on identi-
fying diagnostic or disease screening proteins. Such markers
must display an extremely high speciﬁcity to reliably rule out
those without disease because of the low prevalence of OvCa.
Speciﬁcally, a screening test for OvCa needs to display a sen-
sitivity of more  than 75%, and a speciﬁcity of more  than 99.6%
to attain a PPV of 10% [27,28]. No biomarker has yet to achieve
this level of performance.
3.  Emerging  MS  approaches  for  the
discovery  of  biomarkers  to  diagnose  EOC
As stated previously, proteomic studies in OvCa have been
performed mainly through mass spectrometry (MS) as
this platform allows for the simultaneous examination of
thousands of proteins in a biological sample. In a typical MS-
based experiment, proteins are converted to peptides through
enzyme digestion. These peptides can be fractionated ofﬂine
or placed directly into the mass spectrometer for separation
and ionization. Following ionization, the peptides are frag-
mented in a process known as collision-induced dissociation.
The m/z (mass-to-charge) ratios of the product ions provide
information on the amino acid sequence of the peptide whichgenerated and bioinformatics [29]. Such MS-based discovery
experiments – also known as shotgun proteomics – have rep-
resented the majority of OvCa biomarker studies. Since 2002,
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over 100 studies have been published investigating the pro-
teome of various biological samples relevant to OvCa for novel
biomarkers including serum, proximal ﬂuid, cell lines, and
tumoral tissues. Unfortunately, very few of these putative
markers have passed clinical validation due to inadequate
sensitivity and speciﬁcity for OvCa. As a result, a number of
strategies for OvCa biomarker discovery beyond classical MS-
based proteomics have emerged in the past decade. In the
following sections, we  will examine some of these recent alter-
native approaches that are being increasingly adopted in the
search for novel OvCa biomarkers.
3.1.  Glycomics
Glycomics is the global study of proteins with carbohydrate
post-translational modiﬁcations (PTMs) and has also served
as a growing avenue for biomarker discovery over the past
decade. The addition of carbohydrates to nascent proteins,
also known as glycosylation, is one of the most common PTMs
and is biologically implicated in protein folding, stability, local-
ization, and cell communication [30]. Due to its extensive
involvement in cellular processes, it is speculated that gly-
cosylation is accordingly affected or differentially regulated in
malignant states. As a result, proteins are aberrantly glycosy-
lated and these abnormal glycoforms can be used to detect
the presence of disease. While glycomic analysis of biological
specimens still faces challenges (these will be discussed later),
major advances in both pre-analytical separation methods
and MS  have allowed for increasingly comprehensive char-
acterization of glycomes and cancer-speciﬁc glycoproteins
[31,32]. With respect to OvCa, the majority of glycomic-based
biomarker studies have employed the use of matrix-assisted
laser desorption/ionization (MALDI) MS  coupled with exten-
sive pre-analytical enrichment methods for glycans (such
as peptide-N-glycosidase digestion, chromatographic separa-
tion, and solid phase permethylation) [30].
In a study by Alley Jr. et al., the serum glycomes of 20
healthy control women and 30 OvCa patients were inves-
tigated with a speciﬁc focus on quantitative proﬁling of
the asparagines-linked oligosaccharides (N-linked glycans)
through MALDI MS  [33]. Overall, it was observed that the OvCa
glycomes had increased tri- and tetra-branched structure with
variable sialylation and fucosylation. Further analysis of the
immunoglobulin G-associated glycans revealed an increase
in -galactosylated structures in the OvCa glycomes and
together, these glycan patterns could be used to distinguish
the OvCa patients from the healthy controls. It was however
noted that cancer patients were all diagnosed with late-stage
cancer and further studies with serum from women with stage
I/II cancer are needed to truly assess whether these glycomic
patterns can be used as early detection markers.
In another related study, Saldova et al. analyzed total serum
N-linked glycans in the serum of healthy controls and patients
with OvCa, benign gynaecological conditions and other gynae-
cological cancers using MALDI MS  and electrospray ionization
(ESI) MS  [34]. From these analyses, it was reported that the
OvCa glycome had an increased expression of core fucosy-
lated, -galactosyl biantennary glycans and sialyl Lewis x. As
well, the authors identiﬁed altered glycosylation patterns on i c s 1 ( 2 0 1 3 ) 74–86
acute-phase proteins such as haptoglobin, 1-acid glycopro-
tein, 1-antichymotrypsin and IgG.
Li et al. had also utilized MALDI MS to characterize glycome
of serum derived from OvCa patients and healthy controls [35].
In the subsequent analyses, four glycoproteins of 517, 370, 250
and 163 kilodalton corresponding to two forms of apolipopro-
tein B-199, ﬁbronectin and immunoglobulin A1, respectively,
were identiﬁed as upregulated in the serum of OvCa patients
compared to controls. The glycans subsequently isolated from
these parent proteins consisted of O- and N-linked glycans
that were distinguishable from the corresponding glycans
present in the serum of healthy controls.
Despite the wealth of information that has been accu-
mulated, glycomic-based biomarkers have yet to pass any
clinical validation in OvCa. As mentioned previously, global
investigation of glycosylation and subsequent identiﬁcation
of putative biomarkers remains hampered by biological and
technical limitations. While numerous authors have identi-
ﬁed unique glycomic proﬁles for OvCa, it is unclear whether
such changes are truly OvCa-driven or simply a result of
the metabolic phenomena that ensues after malignancy and
inﬂammation. Thus, additional studies that clearly demon-
strate such glycomic changes as being speciﬁc to OvCa are
required. Due to the heterogeneity and complexity of glyco-
sylation, a prominent technical limitation of glycomics that
has been recognized is the limited ability of current MS
platforms to distinguish glycome isomers [31]. It has been
suggested that cancer-driven glycosylation aberrations may
be traced to the isomeric level where differential expression
of certain isomers are indicative of the presence of speciﬁc
malignancies. Thus, further investigation into resolution of
glycomics-proﬁling by isomers may reveal critical informa-
tion. Finally, a major limitation of glycomic approaches to
biomarker discovery is the availability of validation methods.
The gold-standard quantitative method for validating puta-
tive serum biomarkers is an enzyme-linked immunosorbent
assay, which is based on antibody–antigen interactions to
generate a detectable (and quantiﬁable) signal. Unfortunately,
analogous assays for glycan-based epitopes suffer from poor
reproducibility. There have been attempts to develop lectin- or
antibody-based assays but these capture methods often dis-
play poor speciﬁcity for the glycan epitope of interest and low
sensitivity [36]. Therefore, development of a robust, quantita-
tive method for glycan-based biomarkers is urgently needed in
order to validate candidates that arise from discovery studies.
3.2.  Metabolomics
In addition to glycomics, an equally prominent MS-based
strategy for biomarker discovery has been the investigation
of the metabolome, or the global population of metabolites.
Metabolites are the end products of metabolic pathways which
in turn are a phenotypic reﬂection of the biological sample
under investigation. Thus, it is reasonable to presume that
under a diseased state, metabolic pathways will be altered
and the resultant metabolites will indicate such pathologi-
cal changes. Such metabolic proﬁling has been increasingly
applied to biomarker discovery and has seen some clinical
utility in various malignancies such as breast, colon, oral, and
prostate cancer [37–40].
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With respect to OvCa, metabolomics-based biomarker
iscovery efforts have focused primarily on patient
erum/plasma and urine samples. In three independent
tudies, metabolomic proﬁling of urine from OvCa patients
sing mass spectrometry were able to identify numerous
etabolites with the ability to discriminate between healthy
ontrols and OvCa patients. Zhang et al. were able to iden-
ify 22 metabolites that were able to discriminate between
OC (n = 40) from benign ovarian tumours (BOT; n = 62) and
ealthy controls (n = 54) through ultraperformance liquid
hromatography (UPLC) quadrupole time-of-ﬂight (Q-TOF)
S analysis of urine samples from the said cohorts [41].
ine of these metabolites (imidazol-5-yl-pyruvate, N4-
cetylcytidine, pseudouridine, succinic acid, (S)-reticuline,
-acetylneuraminic acid, 3-sialyl-N-acetyllactoseamine,
-nicotinamide mononucldeotide, and 3′-sialyllactose) were
lso found to be signiﬁcantly different between different-
taged cancers and could reliably distinguish stage I/II
rom stage III/IV cancers. In a similar study by Chen et al.,
etabolomic analysis of OvCa urine through hydrophilic
nteraction chromatography and reversed-phase liquid chro-
atography MS  identiﬁed ﬁve metabolites (two of unknown
dentities, pseudouridine, fragment of pseudouridine, and
hytosphingosine) that were speciﬁc to OvCa patients and
ere signiﬁcantly upregulated compared to healthy con-
rols and BOT patients [42]. Woo et al. identiﬁed three
utative urinary metabolite-based biomarkers for OvCa
1-methyladenosine, 3-methyluridine, and 4-androstene-
,17-dione) through liquid chromatography (LC) MS analysis
43]. The authors noted that the putative metabolic markers
ere also highly involved in oxidative DNA damage and DNA
ethylation processes and thus, metabolomic approaches
re efﬁcient in characterizing metabolic networks present in
alignant states in addition to identifying diagnostic markers.
Similarly, serum/plasma metabolomic studies have
evealed potential diagnostic markers for OvCa. In three
eparate studies, UPLC MS  coupled with partial least-squares
iscriminant analysis was employed to identify metabolic
ifferences between OvCa patients and controls. Chen
t al. identiﬁed 27-nor-5-cholestane-3,7,12,24,25 pentol glu-
uronide (CPG) as a metabolic biomarker to discriminate EOC
rom BOT [44]. In a subsequent validation cohort, serum CPG
isplayed an area under the curve (AUC) of 0.750 in receiver
perator characteristic (ROC) curve analysis for stage I cancer
ith a sensitivity and speciﬁcity of 70% and 77%, respectively.
hrough employing UPLC MS, Fan et al. identiﬁed eight
andidate biomarkers (demethylphylooquinone, ganglioside,
ysophospholipids, ceramides, phytosphingosine, ceramides,
eramides, N′-formylkynurenine) for the diagnosis of EOC.
he authors were able to further validate these markers in an
ndependent cohort and demonstrated that combining all 8
arkers yielded an AUC of 0.941 with a sensitivity of 92% and
 speciﬁcity of 89% for detecting EOC [45]. Zhang et al. also
dentiﬁed six candidate biomarkers (2 of unknown identity,
-piperidinone, l-tryptophan, LysoPC(18:3), and LysoPC(14:0))
or distinguishing EOC from BOT [46]. In subsequent indepen-
ent validation, the combination of the 6 metabolites yielded
 comparable AUC (0.840) to that of CA125 (0.875) overall,
ut a greater AUC among premenopausal patients (0.780 and
.692 respectively). c s 1 ( 2 0 1 3 ) 74–86 79
Urinary and serum metabolomics remains a promising
avenue for OvCa biomarker discovery. The use of metabolites
as disease biomarkers is well-established (such as elevated
glucose for diabetes mellitus) thus lending credence for the
use of such metabolites for OvCa. Unfortunately, MS-based
metabolomics still faces major limitations preventing its
introduction into the clinic for OvCa diagnosis. Biologically,
metabolic responses due to malignancy can vary greatly and
metabolites may undergo extensive biotransformation from
the site of malignancy to bioﬂuid of interest (urine or serum)
[47]. Metabolites may even undergo such processing ex vivo,
and thus, metabolomic studies are susceptible to biases orig-
inating from sample collection and storage. Furthermore,
metabolites can be inﬂuenced by environmental factors such
as smoking, sleep patterns, diet, and age. Therefore, such con-
founding variables can potentially disguise the true effects of
malignancy in metabolomic proﬁling. Future studies will need
to focus on the standardization of metabolomic protocols to
decrease the chances of introducing such biases and also on
intra- and inter-study reproducibility.
3.3.  Peptidomics
Numerous alternative strategies to standard shotgun pro-
teomics have evolved in the past decade in addition to
glycomics and metabolomics. The investigation of the pep-
tidome, or the low-molecular weight proteome, of biological
ﬂuids relevant to OvCa is one such technology. The low-
molecular-weight proteome of both blood and ascites ﬂuid
are believed to contain many  potential diagnostic peptides.
It is hypothesized that metabolic activity increases in tan-
dem with the progression of malignancy and consequently,
protease activity increases as well. Thus, endogenous pep-
tides are generated, some of which may be secreted into
the surrounding environment where they can theoretically be
detected and used to monitor disease. Furthermore, progres-
sion of malignancy is also associated with the degradation
of adhesion and cell-to-cell junction proteins and this may
also be another source of endogenous peptides with diagnos-
tic potential. Although peptidomics is in its infancy, there have
already been a few studies that report the utility of peptides for
OvCa diagnostics. Fredolini et al. reported approximately 51
serum peptidomic markers that were unique to OvCa patients
compared to patients with BOT [48]. On the contrary, Timms
et al. recently reported that MALDI MS peptide proﬁles were
unable to accurately diagnosis OvCa from healthy controls,
though the endogenous peptides could provide some diagnos-
tic insight [49]. However, it has been noted that a limitation
of peptidomic-based approaches is that disciminatory pep-
tides bound to carrier proteins (such as albumin) may be lost
during ofﬂine sample processing. To this end, there exists
some studies that have attempted to mitigate this through
enriching for and/or isolating serum carrier proteins prior to
mass spectrometric analysis to identify novel peptide-based
OvCa biomarkers. In one such study by Lowenthal et al.,
albumin from pooled sera of OvCa patients and non-cancer
controls were isolated and subjected to gel electrophoretic
separation to extract the bound proteins and peptides [50].
Subsequent reversed-phase MS/MS  analysis of the albumin-
bound proteins and peptides revealed over 700 peptides and
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predicted proteins that have not been previously reported
in serum databases. Furthermore, proteolytic fragments of
the cancer-related protein BRCA2 were identiﬁed and veriﬁed
through Western blotting and peptide immunocompetition. In
a related study, Lopez et al. utilized afﬁnity chromatography
coupled with MALDI MS  to decipher the carrier-protein bound
peptidome [51]. From this, the authors were able to identify
a 9 peptide-based biomarker panel that could discriminate
stage I OvCa patients from unaffected healthy controls with
a sensitivity of 93% and speciﬁcity of 97%. Unfortunately, both
of these studies were mainly discovery efforts to establish a
reliable and reproducible workﬂow for the analysis of carrier
protein-bound peptides and have yet to validate their putative
OvCa markers in independent cohorts.
3.4.  Autoantibody  signatures
The identiﬁcation of autoantibody signatures in serum has
also been investigated for OvCa biomarker discovery. OvCa is
often characterized by the complex network of inﬂammatory
cytokines present in the microenvironment and the involve-
ment of immune-related cells such as tumour-associated
macrophages. As such, populations of anti-tumour antibod-
ies may be present and detection of said immunological
responses to tumorigenesis may help to detect early stage
disease. In a laying hen model of human OvCa, Barua et al.
identiﬁed 11 proteins as immunoreactive ovarian antigens
through LC MS  [52]. Although this was the ﬁrst study to
identify immunoreactive ovarian antigens by serum anti-
tumour antibodies, the authors recognized the fact that the
ovarian antigens could not discriminate laying hens with non-
malignant ovarian conditions from those with OvCa. Philip
et al. investigated the immunoproteome of OvCa and healthy
control sera, as well as that of the conditioned media of the
OVCAR3 and SKOV3-A2 cell lines [53]. Overall, 8 autoantibody-
reactive autoantigens were identiﬁed that were present in all
ﬁve cancer serum composites and in both cell lines: A-kinase
anchor protein 9, eukaryotic translation initiation factor 4,
midasin, RAD50, talin 1, vinculin, vimentin, and centrosome-
associated protein 350. Furthermore, the authors identiﬁed a
subset of the MS-generated autoantigens that were implicated
in both humoral (B-cell) and cell-mediated (T-cell) immunity.
However, the suggested novel autoantibody biomarkers for
OvCa diagnosis were not validated in an independent cohort.
Future studies will thus need to address how well such puta-
tive autoantibody-based markers perform in independent,
blinded validation.
3.5.  MALDI-MS  imaging
A ﬁnal approach that has been gaining popularity is MALDI
MS imaging of cancer tissues to identify markers that may be
shed into the extracellular space. In this technique, tissues are
directly subjected to ionization and mass analysis to gener-
ate an array of mass spectra for all positions across the tissue
specimen. As a result, the protein content of speciﬁc regions
of interest can be determined, as well as the spatial distribu-
tion of speciﬁc proteins across the tissue [54]. El Ayed et al. was
able to identify the reg-alpha fragment of the 11S proteasome
activator complex as a putative biomarker through correlative i c s 1 ( 2 0 1 3 ) 74–86
analyses between MALDI MS imaging and immunohistochem-
ical analysis with an anti-reg-alpha C-terminal antibody [55].
Expression of this protein was validated using Western blot
and PCR on the SKOV-3 OvCa cell line. However, the authors
did not validate overexpression of the marker in clinical
samples. Liu et al. were able to extend the approach of MALDI-
MS imaging by combining it with lipidomic analysis via MS
and transcriptomic analysis via laser capture microdissection
to demonstrate that not only are sulfatides upregulated in
OvCa, but that their expression is also localized to the carci-
noma regions as opposed to surrounding stromal and normal
ovarian tissue [56]. Although the authors were able to corre-
late proteomic data with other high-throughput technologies,
the data remains preliminary and discovery-based. Further
investigation into speciﬁc sulfatides and validation in clini-
cal samples is needed to decipher their true clinical utility for
OvCa diagnosis.
Overall, huge advances have been made in the past decade
in terms of innovative uses of MS. No longer are biomarker
discovery studies focused on only proteomic proﬁling, but
are now investigating downstream molecules on a global
scale as markers of OvCa. This paradigm shift represents
the changing perspectives on OvCa pathophysiology in that
it is no longer a genetic disease, but a complex network
of proteins, extracellular interactions and inﬂammation that
leads to malignancy. Despite the advances in technology and
throughput, however, many  OvCa biomarker discovery stud-
ies continue to fail to produce markers that can truly pass
clinical validation across multiple independent cohorts and
this has been attributed to poor study design and biases. As
a result, there have been efforts to implement more  stringent
and standardized protocols for biomarker evaluations to alle-
viate these issues. In 2008, Pepe et al. described a variation
of a nested case–control study for the purposes of biomarker
evaluation (for example between subjects with OvCa and sub-
jects without OvCa) termed prospective-specimen-collection,
retrospective-blinded evaluation (PRoBE) which has begun to
gain prominence in recent biomarker studies [57]. A recent
study by Lee et al. in 2011 investigating the ability of a panel
of 7 biomarkers in addition to CA125 to diagnose preclinical
OvCa also represents the importance of robust study design to
truly assess novel OvCa biomarkers. As opposed to previous
studies that had reported successful validation of the addi-
tion of the 7-biomarker panel to CA125, Lee et al. were able to
conﬁrm that the biomarker panel did not in fact improve pre-
clinical OvCa diagnosis compared to CA125 alone. The authors
were able to attribute this to the fact that earlier studies were
incorrectly using postdiagnostically collected sera as opposed
to truly prediagnostic sera. Despite the wealth of advances in
MS-based biomarker discovery efforts for OvCa, it is clear that
the majority of such approaches still face many  biological and
technical challenges that must be addressed before this new
generation of biomarkers can be introduced into the clinic.
4.  Current  approaches  in  the  treatment  of
EOC
As efforts to improve the early detection of OvCa remain
ongoing, numerous research initiatives are also focused on
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xpanding existing treatment strategies, through the incorpo-
ation of newly  developed targeted therapies into the clinic. In
he following section, we  will brieﬂy highlight current strate-
ies used in the treatment of OvCa, as well as underline recent
dvances made towards the use of molecular targeted thera-
ies in OvCa patient care.
Unlike other solid cancers, the treatment of OvCa has
rogressed very little over the past few decades, as the
rst-line treatment for advanced-stage patients continues
o be a combination of surgical debulking with platinum-
ased chemotherapy (carboplatin or cisplatin) [58]. Although
reatment can prolong survival, many  patients are left with
esidual disease, and ultimately face cancer recurrence. More-
ver, another limitation of standard chemotherapy is the
evelopment of drug resistance, as most patients become
nresponsive to additional rounds of chemotherapy. As such,
he urgent need to identify therapeutic targets that can over-
ome chemoresistance has led to strategies that target the
umour microenvironment, speciﬁcally angiogenesis, as well
s therapies targeting molecular pathways that are frequently
xpressed in OvCa tumours [59,60].
Targeting the tumour microenvironment through the abro-
ation of angiogenesis mechanisms has proven to be an
ffective strategy for advanced OvCa. The importance of new
lood vessel formation via increased production of vascu-
ar endothelial growth factor A (VEGF-A) in the growth and
etastasis of OvCa tumours has led to a series of clinical
rials evaluating the efﬁcacy of the VEGF-A inhibitor, beva-
izumab, along with conventional chemotherapeutic agents
61,62]. Two phase III clinical trials have shown that admin-
stration of bevacizumab during and after carboplatin and
aclitaxel treatment can prolong progression-free survival
PFS) in patients with advanced OvCa and for those with high
isk of disease progression [61,62]. However, slight decreases
n the quality of life of patients were reported with contin-
al bevacizumab treatment [63]. Based on the results of these
rials, the use of bevacizumab in combination with standard
hemotherapy has been approved in Europe. Moreover, similar
ncreases in PFS were also observed when bevacizumab was
dministered during and after chemotherapeutic treatment
n platinum-sensitive recurrent OvCa [64]. These ﬁndings
uggest that it may also be useful in the treatment of platinum-
ensitive relapsed patients, however; further evaluation is
eeded to elucidate the appropriate use of bevacizumab in the
anagement of OvCa.
In addition to anti-angiogenic therapies, other promis-
ng targeted therapies include those that disrupt aber-
ant signalling pathways that become activated in OvCa
umours. These include inhibitors against PI3K/AKT/mTOR
nd Ras/Raf/MEK/ERK pathways, which have higher muta-
ion rates in clear cell/endometrioid and low-grade serous
varian tumours/mucinous, respectively [60,65]. As a result,
hese agents provide an attractive option for the treatment
f rarer OvCa subtypes, as they typically show no response
o standard chemotherapies. Randomized controlled trials are
eeded to assess the clinical utility of these drugs, as well as
heir potential to treat patients that have developed resistance
o platinum- and taxane-induced cytotoxicity.
Lastly, disrupting DNA repair machinery using Poly(ADP-
ibose) polymerase (PARP) inhibitors is a promising strategy for c s 1 ( 2 0 1 3 ) 74–86 81
treating OvCa patients harbouring BRCA1 or BRCA2 mutations
[60]. As BRCA1/2 proteins are essential to the homologous
recombination repair pathway, preventing single-stranded
DNA break repair with PARP inhibitors will lead to an accumu-
lation of double-stranded breaks, which will induce apoptosis
in BRCA-deﬁcient tumour cells [65]. Whether these inhibitors
will have more  effectiveness as a single agent or in combi-
nation with therapies still requires further investigation, as
this may depend on the histological and molecular tumour
subtype of the patient.
Overall, it is evident that the future of OvCa treatment and
management will involve a combinatorial approach, as con-
ventional therapies will be used in combination with newly
developed agents. Further investigation on the appropriate
administration of the above therapies will be a focus of upcom-
ing efforts, as ongoing clinical trials will assess the clinical
utility of these drugs as well as determine which patients will
beneﬁt the most from each therapeutic agent.
5.  Comparative  proteomics  to  identify
proteins  associated  with  chemoresistance
Despite the major emphasis placed on the search for early
detection biomarkers through proteomic proﬁling and other
alternative biomarker discovery efforts, these studies do not
allow for the identiﬁcation of markers that could guide treat-
ment nor predict its response in patients. As such, attempts
have been made towards uncovering proteomic changes that
occur as a result of chemoresistance. These include proﬁling
chemosensitive and resistant cancer cell lines and tissues,
as a starting point in understanding the molecular basis of
resistance to chemotherapeutic agents, which will ultimately
lead to the identiﬁcation of markers for treatment response as
well as the discovery of novel therapeutic targets. In the fol-
lowing sections, we will describe a few of the emerging cell
line-based proteomic strategies, including quantitative pro-
teomics, glycoproteomics, and organellar proteomics to study
chemoresistance. In addition, the use of tissue proteomics to
complement the above strategies will be discussed.
5.1.  Cell  line-based  proteomics
EOC cell lines provide a valuable biological source for con-
ducting high-throughput proteomics because of their easy
manipulation and the ability to mine the proteome in depth.
Using the human OvCa cell line, A2780, which was derived
from an untreated patient, numerous studies have gener-
ated its platinum- and taxane-resistant derivatives in order
to compare proteomic changes between the two  conditions,
or to an inherently resistant cancer cell line, OVCAR3 [66–70].
Findings from these studies revealed that protein expression
changes occurred in pathways regulating stress response, apo-
ptosis, metabolism, cell cycle, and protein biosynthesis [67,68].
For instance, Cicchillitti et al. identiﬁed disulphide isomerase
ERp57 as a novel paclitaxel-resistant marker that forms a
complex with TUBB3, and directs microtubule attachment to
chromosomes, which is interesting given that paclitaxel tar-
gets tubulin [68]. Further studies should examine the effects
of ERp57 knockdown on decreasing resistance to paclitaxel
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in other OvCa cell lines, as well as evaluate the potential of
ERp57 to be used a marker to monitor therapy and patient
outcome. Similar studies incorporated 2-dimensional gel elec-
trophoresis (2-DE) coupled to ESI Q-TOF tandem MS/MS or
MALDI-TOF MS  in the analysis of A2780 and SKOV3 platinum
and taxane-sensitive and -resistant cell lines, and identiﬁed
numerous potential markers of resistant OvCas for personal-
ized cancer therapy [69–71]. However, additional evaluation of
these proteins in large clinical validation studies is required to
elucidate their potential as predictive markers of chemoresis-
tance. Further examination on the role of these proteins in the
development of platinum resistance using knockout mouse
models will determine their value as potential therapeutic
targets. Other cell line model systems of chemoresistance,
such as IGROV1 (sensitive) and IGROV1-R10 (resistant) cells
have also been employed in the quest to ﬁnd altered pro-
teomic signatures of resistance, which have been followed
up with a kinetic analysis [72,73]. Through this analysis, Le
Moguen et al. identiﬁed time and concentration-dependent
changes in protein levels associated with pathways linked
to stress, oxidative stress response, glycolysis, and cell com-
munication [73]. Overall, these initial studies have unravelled
potential molecular pathways that become disrupted during
chemoresistance. Using this knowledge, speciﬁc experiments
may be conducted to elucidate the mechanisms underlying
resistance, as the above approaches only provided a global
snapshot of platinum-resistance associated proteins.
5.1.1.  Quantitative  proteomics
The studies highlighted above employed a qualitative
approach to identifying markers of chemoresistance. In order
to achieve more  accurate protein quantiﬁcation between
different conditions, a few studies have applied labelling
techniques as a means to quantify protein expression
changes. For instance, isotope labelling via isotope-coded
afﬁnity tag (ICAT) and isobaric tag for relative and abso-
lute quantiﬁcation (iTRAQ) has also been incorporated into
comparative proteomic studies as it allows for easy quan-
tiﬁcation of proteins between different conditions, which
is often completed in fewer MS  runs compared to non-
labelling approaches. In particular, Shetty et al. utilized iTRAQ
labelling to identify drug resistant tumour antigens in SKOV3-
A2 (cisplatin-resistant), SKOV3-A2-CP (cisplatin-treated), and
OVCAR3 (cisplatin-sensitive) OvCa cell lines, which could be
used for immunotherapeutic targeting with antigen-speciﬁc
vaccines [74]. Overall, the authors found that cisplatin treat-
ment of platinum-resistant OvCa cells increased MHC  Class I
presentation of peptides derived from various proteins impli-
cated in cancer [74]. In another study, iTRAQ was used to
quantify protein expression between the cisplatin-sensitive
cell line, COC1, and its resistant subline, COC1/DDP, which
revealed decreased and increased levels of two proteins, PKM2
and HSPD1, respectively, in resistant cancer cells [75]. Subse-
quent functional knockdown of PKM2 and HSPD1 revealed that
these proteins play a role in cell viability, and therefore, may
serve as potential therapeutic targets [75]. Moreover, Stewart
et al. used another form of isotope labelling, ICAT, to com-
pare the proteome of sensitive and resistant IGROV-1 cancer
cells, in which differentially expressed proteins were then cor-
related with mRNA  expression; however, due to suggested i c s 1 ( 2 0 1 3 ) 74–86
post-transcriptional mechanisms, the majority of candidates
did not display the same changes in expression at both the
protein and mRNA  levels [76].
5.1.2.  Glycoproteomics
Besides looking at total protein expression as a whole, another
approach to studying chemoresistance involves the study of
glycoproteomics. During cancer progression, protein PTMs,
particularly glycosylation, display altered expression patterns,
which may contribute to the malignancy of the disease as
discussed previously. Glycan structures may also contribute
to various biological processes that promote tumorigenesis
and encourage metastatic behaviour. Therefore, analyzing
alterations of glycan structures has been a viable method
for the discovery of markers related to chemoresistance.
Enrichment and characterization of the glycoproteome from
A2780-sensitive and -resistant cell lines has also led to the
identiﬁcation of a few glycoproteins, including CD70, tumour
rejection antigen (gp96) 1, triose phosphatase isomerase,
palmitoyl-protein, thioesterase 1 precursor and ER-associated
DNAJ, which represent putative markers of chemotherapy
resistance [66,77]. Interestingly, the majority of proteins iden-
tiﬁed through glycoprotein enrichment were not uncovered
in proteomic analyses of the entire proteome, which under-
lines its advantage in discovering low-abundant markers of
drug resistance [77]. Subsequent validation of these ﬁndings
in clinically annotated patient tumour samples may lead to
the incorporation of these markers into the clinic, which will
be important before analyzing these markers as therapeutic
targets.
5.1.3.  Organellar  proteomics
Proteomic technologies have also been applied to character-
ize the proteomes of subcellular organelles, which is useful
for gaining insight into their biological function during var-
ious diseased states. It has been recognized that the ability
of malignant cells to evade apoptosis may play a major role
in the resistance of tumour cells to chemotherapeutic agents.
Since mitochondria control the intrinsic apoptotic pathway,
a few studies have examined the differential protein expres-
sion in the mitochondria of platinum-resistant OvCa cell lines
[78,79]. Using an organellar proteomic approach, Chappell
et al. used label-free proteomics to quantify differences in
protein expression between cisplatin-sensitive (A2780) and
resistant (A2780-CP20) OvCa cell lines, which resulted in
elevated expression of ALCAM and AKAP12, and decreased
expression of Nestin [78]. In a comparable study, a 2-DE pro-
teomic analysis revealed a decreased expression of prohibitin
in platinum-resistant cell lines, which was conﬁrmed in tis-
sues from patients who were resistant to chemotherapy [79].
Taken together, these ﬁndings highlight the use of proteomic
applications towards the understanding of mitochondrial dys-
function in platinum-resistant OvCa.
5.1.4.  Limitations  of  cell  line-based  approaches
In general, the aforementioned studies have resulted in
an indispensable amount of information regarding molec-
ular mechanisms implicated in chemoresistance, and have
provided numerous potential markers that may serve as indi-
cators of drug response. However, several limitations of these
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tudies prevent the incorporation of these markers into the
linic. For instance, the majority of these studies were con-
ucted on one or two OvCa cell lines, which surely do not
apture the heterogeneity of this disease [80]. Since in vitro
ndings do not always translate to what is observed in vivo,
ll of these markers need to be conﬁrmed using human sam-
les, such as tissues, serum, and proximal ﬂuids. Another
imitation of using in vitro cell lines is that it is not repre-
entative of the tumour–host interactions that occur in the
ancer microenvironment [80]. Future studies should focus
n more  targeted approaches that measure speciﬁc protein
evels in clinically well-deﬁned samples. For example, Kim
t al. used selective reaction monitoring-based quantiﬁcation
o measure the levels of a SOD1, which has been shown to pre-
ent chemotherapeutic-induced apoptosis in OvCa cells [81].
s such, this method will be useful for subsequent studies
hat aim to validate or verify these proteins in various biologi-
al samples. Lastly, the results from these studies suggest that
umerous proteomic alterations occur during drug resistance.
uture studies may beneﬁt by combining these ﬁndings to
elineate common pathways dysregulated in chemoresistant
ells. Targeting molecular pathways may be a more  practical
pproach to treating resistant tumours, and thereby, provid-
ng a more  effective way for tailoring personalized patient
are.
.2.  Tissue  proteomics
iases present in cell line-based models have emphasized the
mportance of using biological samples that recapitulate the
isease, and thus, have led to tissue proteomics as another
lternative to understanding chemoresistance. Thus far, a
ew approaches have been carried out to characterize dif-
erential protein expression between primary and recurrent
vCa tissues [82–85]. For example, using quantitative pro-
eomics via ICAT, Pan et al. compared the expression between
 chemosensitive and a chemoresistant tissue harvested at
rimary debulking surgery prior to chemotherapy to identify
hich proteins are responsive to it [82]. These differential
xpressions were then correlated with gene expression pro-
les of similar tissues, which revealed that proteins related
o cell junctions and the extracellular matrix, become altered
uring chemotherapy [82]. Another study used paired primary
nd recurrent post-chemotherapy samples from high-grade
erous OvCa patients to identify numerous proteins elevated
n recurrent tissues, which were also conﬁrmed by gene
xpression analysis [83]. Subsequent knockdown of these pro-
eins in carboplatin-resistant cell lines using short hairpin
NA, identiﬁed RELA, the p65 subunit of NF-kB, and STAT5,
s modulators of drug resistance [83]. As a result, inhibi-
ion of both proteins reduced the chemoresistance potential
f cancer cell lines, and therefore, may represent a novel
reatment for recurrent OvCa platinum-resistant patients [83].
nterestingly, both studies used an integrated approach to ﬁnd
hemoresistant makers, as they employed gene expression
roﬁling to validate their proteomic discovery data. Perhaps,
uture efforts may beneﬁt from integrating data obtained
rom genomic, transcriptomic, and proteomic approaches as
eans to understanding the molecular basis of chemore-
istance. Moreover, Kim et al. used the differential protein c s 1 ( 2 0 1 3 ) 74–86 83
expression proﬁles of chemosensitive and chemoresistant tis-
sues obtained from 2-DE to construct a two marker panel,
SGEF and keratin 1, to serve as predictive markers for
chemoresistant disease with a sensitivity and speciﬁcity of
80% and 92% respectively [84]; however, although promis-
ing, these markers require further validation in larger sample
cohorts.
Lastly, rather than focusing on individual proteins, bio-
logical signalling pathways could also be used as targets for
overcoming chemoresistance. A recent study investigated the
expression of proteins from molecular pathways associated
with OvCa progression [85]. Using reverse phase protein arrays
and normalized CA125 values, numerous proteins from the
TGF- pathway were implicated in playing a role in chemore-
sistance in high-grade serous OvCa [85].
Overall, the importance of using biological tissues for
discovery is evident through the various studies that impli-
cate different biological pathways in drug resistance. Given
that none or very few protein expression changes are com-
mon  between the different studies, we have to question
whether tissue proteomics is a viable route for investigat-
ing chemoresistance. Alternatively, the lack of consistent
results may be due to the heterogeneity of the disease as
well as patient-to-patient variability. In addition, biases from
the methodologies used, including pre-analytical and post-
analytical variables, may also have an effect on the variability
and reproducibility between studies. Since OvCa is a com-
plex disease, future studies need to be conducted to limit
biases by having a standard protocol for tissue collection,
using paired primary and recurrent tissue from the same
patient, as well as taking into account the subtypes of the
disease.
6.  Future  perspectives
Overall, it is evident that proteomic and MS-based technolo-
gies have yielded an indispensable amount of information,
which has been useful for the understanding of proteomic
alterations that occur during OvCa pathogenesis. In terms
of diagnostics, the use of shotgun proteomics has been rel-
atively disappointing due to the wealth of novel markers
“identiﬁed”, yet few have passed clinical validation. The
lack of markers has thus necessitated this surge of inno-
vative MS-based biomarker discovery techniques such as
glycomics and metabolomics. Whether or not these tech-
niques will identify the elusive novel biomarker(s) for OvCa
remains to be seen as the majority of the approaches, how-
ever promising, are still in their infancy and there still exists
many  technical limitations that have yet to be overcome.
On the other hand, proteomic studies aimed at identify-
ing markers of therapeutic response are only beginning to
emerge. Although several mechanisms of chemoresistance
and potential markers of drug response have been unrav-
elled, these studies are also subjected to their own biases
and limitations. Future efforts should focus on using biologi-
cally relevant samples that capture the heterogeneity of the
disease, as well validating ﬁndings in independent sample
cohorts.
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